logo

IOBT

IO Biotech·NASDAQ
--
--(--)
--
--(--)
4.39 / 10
Netural

Corporate fundamentals rate fair at 4.4/10. Key positives include a strong inventory turnover ratio (47.88) and solid interest coverage (15.51), but these are offset by a concerning net-profit-to-total-profit ratio (97.60) and negative asset-market-value deviation (-0.507). Revenue growth is robust YoY (92.79%), yet the overall balance sheet and profitability metrics remain constrained, warranting caution.

Fundamental(4.39)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight21.80%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.41%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-1.81%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight17.50%
1M Return8.99%
PB-ROE
Value-0.88
Score2/3
Weight23.43%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-1.89%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.16%
1M Return0.10%
Asset-MV
Value-0.51
Score2/3
Weight24.95%
1M Return12.15%
Net profit / Total profit (%)
Value97.60
Score1/3
Weight-2.34%
1M Return-1.59%
Cash-MV
Value-0.07
Score2/3
Weight16.80%
1M Return8.80%
Is IOBT fundamentally strong?
  • IOBT scores 4.39/10 on fundamentals and holds a Fair valuation at present. Backed by its -237.93% ROE, 0.00% net margin, -0.29 P/E ratio, 27.64 P/B ratio, and -3.88% earnings growth, these metrics solidify its Netural investment rating.